Ian Gourley
M.D., Senior Director,
Translational Medicine Science, Immunology Therapeutic Area
Janssen Research & Development, LLC
United States of America
Biography
The goal is to maximize the 'learnings' from the translational medicine early development studies, answering key development questions for the project such as understanding the mechanism of action (MOA) of the drug, not just obtaining data on safety and pharmacokinetics (PK)," said Donald Raible, M.D., head of Translational Medicine Development at Janssen R&D.
Research Interest
http://www.fiercebiotech.com/r-d/industry-voices-contributions-of-immunology-translational-medicine-to-clinical-pharmaceutical
